Abivax prices $800 million ADS offering, cites Phase 3 UC maintenance data

Abivax S.A. filed a prospectus supplement dated June 30, 2026 for a public offering of 6,400,000 American Depositary Shares, each representing one ordinary share with a nominal value of 0.01 per share.¹ The public offering price was set at $125.00 per ADS, with total proceeds to the company before expenses of $762,000,000 after underwriting discounts and commissions of $38,000,000.¹ Delivery of the ADSs is expected on or about July 6, 2026, and underwriters have an option, exercisable before that settlement date, to purchase up to 960,000 additional ADSs at the offering price.¹

The filing said the company intends to use net proceeds for expenses relating to potential commercialization of obefazimod in the United States, clinical research and development expenses primarily related to ulcerative colitis and Crohn's disease, and remaining amounts for general corporate purposes.¹ Abivax said it believes the net proceeds, together with existing cash, will be sufficient to meet working capital requirements into the second quarter of 2029.¹

The filing also disclosed topline results from Part 2 of the Phase 3 "ABTECT" 44-week maintenance trial, announced June 29, 2026. Among induction non-responders treated continuously with 50 mg obefazimod, patients demonstrated clinical remission of 37.2%, clinical response of 61.5%, endoscopic improvement of 48.0%, HEMI of 44.6%, and endoscopic remission of 34.5% at Week 44.¹ On safety, the company said no new safety pattern emerged with the additional cumulative exposure provided by Part 2.¹ Abivax reiterated it remains on track to submit its NDA to the FDA in the fourth quarter of 2026.¹